Skip to main content
SpringerLink
Log in

Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Considerable interest in the roles of serine proteases and serine protease inhibitors (serpins) in regulating physiologic and pathologic tissue remodeling has led to studies that indicate their critical participation in development and diseases of the brain. Plasminogen activator inhibitor-1 (PAI-1) is the most significant regulator of fibrinolysis in plasma, but little is known of the levels or activities of this important serpin in normal brain and brain tumors. For this reason, we estimated qualitative and quantitative levels of PAI-1 in normal human brain and various brain tumors. Western-blot results indicated that a 51 kDa band recognized with polyclonal anti-PAI-1 was more prominently in metastatic and glioblastoma than in meningiomas and lowgrade gliomas; normal human brain lacked any detectable band. Reverse zymography also showed high levels of PAI-1 in malignant brain tumors. The complex formation with125I-urokinase demonstrated that PAI-1 complex levels were increased in metastatic and glioblastoma when compared with low-grade gliomas and meningiomas. Since PAI-1 acts as a modulator of fibrinolysis, a better understanding of the balance between serine proteases and PAI-1 is likely to enhance our knowledge of brain tumor biology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gerdin B, Saldeen T: Effect of fibrin degradation products on microvascular permeability. Throm Res 13: 995–1006, 1978

    Google Scholar 

  2. Ng R, Kellen JA: The role of plasminogen activators in metastasis. Med Hypotheses 10: 291–293, 1983

    PubMed  Google Scholar 

  3. Ossowski L, Biegel D, Reich E: Mammary plasminogen activator: Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 16: 929–940, 1979

    PubMed  Google Scholar 

  4. Strickland S, Reich E, Sherman MI: Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and partial endoderm. Cell 9: 231–240, 1976

    PubMed  Google Scholar 

  5. Unkeless JC, Gordon S, Reich E: Secretion of plasminogen activator by stimulated macrophages. J Exp Med 139: 834–850, 1974

    PubMed  Google Scholar 

  6. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen B, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 49: 139–266, 1985

    Google Scholar 

  7. Frame MC, Freshney RI, Vaughan PF, Graham DI, Shaw R: Interrelationship between differentiation and malignancy-associated properties in glioma. Br J Cancer 49: 269–280, 1984

    PubMed  Google Scholar 

  8. Paganetti PA, Caroni P, Schwab ME: Glioblastoma infiltration into the central nervous system tissuein vitro: Involvement of a metalloprotease. J Cell Biol 107: 2281–2291, 1988

    PubMed  Google Scholar 

  9. Granelli-Piperno A, Reich E: A study of proteases and protease inhibitor complexes in biological fluids. J Exp Med 148: 223–234, 1978

    PubMed  Google Scholar 

  10. Wachman JT, Biedler JL: Fibrinolytic activity associated with human neuroblastoma cells. Exp Cell Res 86: 264–268, 1974

    PubMed  Google Scholar 

  11. Pittman RN: Release of plasminogen activator and a calcium-dependent metalloprotease from cultured sympathetic and sensory neurons. Dev Biol 110: 91–101, 1985

    PubMed  Google Scholar 

  12. Krystosek A, Seeds NW: Plasminogen activator secretion by granule neurons in cultures of developing cerebellum. Proc Natl Acad Sci USA 78: 7810–7814, 1981

    PubMed  Google Scholar 

  13. Valinsky JE, LeDouarin NM: Production of plasminogen activator by migrating cephalic neural crest cells. EMBO J 4: 1403–1406, 1985

    PubMed  Google Scholar 

  14. Krystosek A, Seeds NW: Plasminogen activator release at the neuronal growth cone. Science 213: 1532–1534, 1981

    PubMed  Google Scholar 

  15. Zisapel N, Miskin R, Landon M, Soreq H: Plasminogen activator is enriched in the synaptosomal plasma membranes. Brain Res 248: 129–139, 1982

    PubMed  Google Scholar 

  16. Takashima S, Koga M, Tanaka K: Fibrinolytic activity of human brain and cerebrospinal fluid. Br J Exp Path 50: 533–539, 1969

    Google Scholar 

  17. Glas P, Astrup T: Thromboplastin and plasminogen activator in tissues of the rabbit. Am J Physiol 219: 1140–1146, 1970

    PubMed  Google Scholar 

  18. Bykowska K, Rijken DC, Collen D: Purification of characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture. Thromb Haemost 46: 642–644, 1981

    PubMed  Google Scholar 

  19. Danø K, Dabelsteen E, Nielsen LS, Kaltoft K, Wilson EL, Zeuthen J: Plasminogen-activating enzyme in cultured glioblastoma cells: An immunofluorescence study with monoclonal antibody. J Histochem Cytochem 30: 1165–1170, 1982

    PubMed  Google Scholar 

  20. Gilbert LC, Wachsman JT: Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH: A comparison with human urokinase. Biochim Biophys Acta 704: 450–460, 1982

    PubMed  Google Scholar 

  21. Hince TA, Roscoe JP: Fibrinolytic activity of cultured cells derived during ethylnitrosourea-induced carcinogenesis of rat brain. Br J Cancer 37: 424–433, 1978

    PubMed  Google Scholar 

  22. Hince TA, Roscoe JP: Differences in pattern and levels of plasminogen activator production between a cloned cell line from an ethylnitrosourea-induced glioma and one from normal adult rat brain. J Cell Physiol 104: 199–207, 1980

    PubMed  Google Scholar 

  23. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danø K: Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21: 6410–6415, 1982

    PubMed  Google Scholar 

  24. Soreq H, Miskin R: Plasminogen activator in the rodent brain. Brain Res 216: 361–374, 1981

    PubMed  Google Scholar 

  25. Tucker WS, Kirsch WM, Martinez-Hernandez A, Fink LM:In vitro plasminogen activator activity in human brain tumors. Cancer Res 38: 297–302, 1978

    PubMed  Google Scholar 

  26. Wilson EL, Becker MLB, Hoal EG, Docodle EB: Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res 40: 933–938

  27. Kruithof EKO: Inhibitors of plasminogen activators, in Kluft C (ed): Tissue-Type Plasminogen Activator (tPA): Physiological and Clinical Aspects. Boca Raton, CRC Press, Inc., 1988, pp 190–210

    Google Scholar 

  28. Carrel RW: α1-Antitrypsin molecular pathology, leukocytes and tissue damage. J Clin Invest 78: 1427–1431, 1986

    PubMed  Google Scholar 

  29. Baker JB, Low DA, Simmer RL, Cunningham DD: Protease nexin: A cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21: 37–45, 1980

    PubMed  Google Scholar 

  30. McGrogan M, Kennedy J, Li MP, Hsu C, Scott RW, Simonsen C, Baker JB: Molecular cloning and expression of two forms of human protease nexin I. Biotechnology 6: 172–177, 1988

    Google Scholar 

  31. Loskutoff DJ, Edgington TS: Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. J Biol Chem 256: 4142–4145, 1982

    Google Scholar 

  32. My T, Sawday M, Lawrence D, Millan JL, Loskutoff DJ: Cloning and sequence of a cDNA coding for the human β-migrating endothelial cell type plasminogen activator inhibitor. Proc Natl Acad Sci USA 83: 6776–6780, 1986

    PubMed  Google Scholar 

  33. Holmberg L, Lecander I, Persson B, Astedt B: An inhibitor from placenta specifically binds urokinase and inhibitor plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 544: 128–137, 1978

    PubMed  Google Scholar 

  34. Ye RD, Ulun TC, Sadies JE: cDNA cloning and expression inEscherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 262: 3718–3725, 1987

    PubMed  Google Scholar 

  35. Heeb MJ, Espana F, Geiger M, Collen DC, Stump DC, Griffin JH: Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 262: 15813–15816, 1987

    PubMed  Google Scholar 

  36. Stump DC, Thienpont M, Collen D: Purification and characterization of a novel inhibitor of urokinase from human urine quantitation and preliminary characterization. J Biol Chem 261: 12759–12766, 1986

    PubMed  Google Scholar 

  37. Ericksen LA, Hekman CM, Loskutoff DJ: The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum and plasma are immunologically related. Proc Natl Acad Sci USA 82: 8710–8714, 1985

    PubMed  Google Scholar 

  38. Hekman C, Loskutoff DJ: Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260: 11581–11587, 1986

    Google Scholar 

  39. Rao JS, Baker JB, Morantz RA, Kimler B, Evans R, Festoff BW: Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: Evidence for elevated expression of protease nexin I-like inhibitors and a novel sodium dodecyl sulfate-activated tumor antithrombin. Cancer Res 50: 5039–5044, 1990

    PubMed  Google Scholar 

  40. Deutsch DG, Mertz ET: Plasminogen: Purification from human plasma by affinity chromatography. Science 170: 1095–1096, 1970

    PubMed  Google Scholar 

  41. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T-4. Nature 227: 680–685, 1970

    PubMed  Google Scholar 

  42. Towbin H, Staehlin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications. Proc Natl Acad Sci USA 76: 4350–4356, 1979

    PubMed  Google Scholar 

  43. Hantaï D, Rao JS, Kahler C, Festoff BW: Decrease in plasminogen activator correlates with synapse elimination during neonatal development of mouse skeletal muscle. Proc Natl Acad Sci USA 86: 362–366, 1989

    PubMed  Google Scholar 

  44. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein binding. Anal Biochem 72: 248–254, 1976

    PubMed  Google Scholar 

  45. Baker MS, Bleakley P, Woodrow CG, Doe WF: Inhibition of cancer cell urokinase plasminogen activity by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 50: 4676–4684, 1990

    PubMed  Google Scholar 

  46. Gloor S, Odink K, Guenther J, Nick H, Monard D: A gliaderived neurite promoting factor with protease inhibitory activity belongs to the protease nexins. Cell 47: 687–693, 1986

    PubMed  Google Scholar 

  47. Gross JL, Behrens DL, Mullins DE, Kornblith PL, Dexter DL: Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res 48: 291–296, 1988

    PubMed  Google Scholar 

  48. Keohane ME, Hall SW, Vandenberg SR, Goniar SL: Secretion of α2-macroglobulin, α2-antiplasmin and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture. J Neurosurg 79: 234–241, 1990

    Google Scholar 

  49. Quax PHA, Van Leeuwen RTJ, Verspaget HW, Verheijen JW: Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 50: 1488–1494, 1990

    PubMed  Google Scholar 

  50. Sitrin RG, Gyetko MR, Kole KL, McKeever P, Varani J: Expression of heterogenous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. Cancer Res 50: 4957–4961, 1990

    PubMed  Google Scholar 

  51. Rehemtulla A, Murphy P, Douson M, Hort DA: Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma U138. Biochem Cell Biol 66: 1270–1277, 1988

    PubMed  Google Scholar 

  52. Klinger KW, Winquist R, Riccio A, Anderasen PA, Sartorio R, Mielsen LS, Stuart N, Stanisloviti P, Watkins P, Douglas R: Plasminogen activator inhibitors type I gene is located at region q21.3–q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84: 8548–8552, 1987

    PubMed  Google Scholar 

  53. Medcalf RL, Kruithod EK, Schleuning WD: Plasminogen activator inhibitors 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 168: 751–759, 1988

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Jasti S. Rao, Alan Rayford & Raymond Sawaya

  2. Brain Tumor Institute, 64132, Kansas City, Missouri, USA

    Robert A. Morantz

  3. Department of Veterans Affairs Medical Center, Neurobiology Research Laboratory, 64128, Kansas City, Missouri, USA

    Barry W. Festoff

Authors
  1. Jasti S. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Rayford
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Morantz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barry W. Festoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raymond Sawaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rao, J.S., Rayford, A., Morantz, R.A. et al. Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. J Neuro-Oncol 17, 215–221 (1993). https://doi.org/10.1007/BF01049977

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01049977

Key words

Search

Navigation